Virax Biolabs Introduces Monkeypox Virus Antigen Rapid Test Kit – VRAX Stock Short Squeeze
LONDON, Sept. 20, 2022 /PRNewswire/ — Virax Biolabs (“Virax” or the “Company”) (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of a Monkeypox Virus Antigen Rapid Test Kits which has been launched in markets accepting the CE mark, such as the European Union. The test kits are for use in point of care settings and can help healthcare professionals accurately identify a monkeypox infection in people suspected of carrying the monkeypox virus with results typically available in 15 minutes. It also serves as a valuable initial screening test for individuals that have been exposed to monkeypox infected patients or a high-risk environment. The specialized diagnostic kits can be found by contacting the company’s sales representatives.
| Short Interest | 90,153 shares |
| Short Interest Ratio | 0.35 Days to Cover |
| Short Interest % Float | 1.92% |
| Off-Exchange Short Volume | 59,886 shares – source: FINRA (inc. Dark Pool volume) |
| Off-Exchange Short Volume Ratio | 51.34% – source: FINRA (inc. Dark Pool volume) |
Last update: now
| Time Since Last Change | Timestamp (UTC) | VRAX Short Shares Availability |
|---|---|---|
| 1 hour ago | 2022-09-20 12:51:42.223 | 0 |
| 1 hour ago | 2022-09-20 12:21:42.223 | 50,000 |
| 2 hours ago | 2022-09-20 11:50:44.293 | 100,000 |
| 3 days ago | 2022-09-17 02:20:49.333 | 150,000 |
